CompletedPhase 2NCT00014209
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NCIC Clinical Trials Group
- Principal Investigator
- Michael R. Crump, MD, FRCPCPrincess Margaret Hospital, Canada
- Intervention
- cisplatin(drug)
- Enrollment
- 77 enrolled
- Eligibility
- 16-120 years · All sexes
- Timeline
- 2000 – 2009
Study locations (13)
- Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- Moncton Hospital, Moncton, New Brunswick, Canada
- Newfoundland Cancer Treatment and Research Foundation, St. John's, Newfoundland and Labrador, Canada
- Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
- Kingston Regional Cancer Centre, Kingston, Ontario, Canada
- Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
- Credit Valley Hospital, Mississauga, Ontario, Canada
- Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada
- Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Humber River Regional Hospital, Weston, Ontario, Canada
- Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor, Ontario, Canada
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00014209 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic